Federated Hermes’s Vor Biopharma VOR Stock Holding History

Federated Hermes’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-99	Closed	-$1.42K	–	2200
2025 Q1	$1.42K	Sell	99 -53	-35%	-$1.27K	﹤0.01%	1978
2024 Q4	$3.38K	Sell	152 -36	-19%	-$597	﹤0.01%	1930
2024 Q3	$2.63K	Buy	188 +8	+4%	+$146	﹤0.01%	1925
2024 Q2	$3.6K	Buy	+180	New	+$5.82K	﹤0.01%	1867
2022 Q2	–	Sell	-4	Closed	-$1K	–	2289
2022 Q1	$1K	Buy	+4	New	+$681	﹤0.01%	2123

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Federated Hermes's VOR Position: Q2 2025 in Review

Federated Hermes sold out of Vor Biopharma (VOR) in Q2 2025, closing a stake of 99 shares — an estimated $1.42K sold.

Federated Hermes first reported a position in VOR in Q1 2022 and held it in 5 quarters. The position peaked at $3.6K in Q2 2024. 35 funds tracked by Wall St. Rank hold VOR as of Q2 2025.

Federated Hermes reported no remaining Vor Biopharma position as of Q2 2025 after selling out during the quarter.
Federated Hermes sold 99 Vor Biopharma shares in Q2 2025, an estimated $1.42K.
Federated Hermes first reported a position in Vor Biopharma in Q1 2022 and held it in 5 quarters.
Federated Hermes's Vor Biopharma position peaked at $3.6K in Q2 2024.
35 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2025.

Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.